AstraZeneca's camizestrant improves survival vs Faslodex in phase 2 breast cancer trial
Sundry Photography


AstraZeneca (NASDAQ:AZN) said its medicine camizestrant showed survival benefit over its other drug Faslodex (fulvestrant) in certain patients with breast cancer in a phase 2 trial called SERENA-2.
The British pharma giant said on Wednesday that camizestrant met the main goal of showing a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg dose levels, compared to Faslodex 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy for advanced disease.

PFS is the length of time during/after therapy a patient lives with the disease without it getting worse.
In the study, 240 patients were given camizestrant or Faslodex until disease progression.
AstraZeneca added that camizestrant was well tolerated, and its safety profile was consistent with that seen in previous trials with no new safety signals.
"Our goal with our next generation oral SERD camizestrant is to improve on currently available endocrine therapies for patients with HR-positive breast cancer in early and metastatic disease," said Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca.
AZN +3.15% to $57.66 premarket Oct. 26